Date:9/24/2010

e may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation, including domestic and foreign health care reform, affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; our ability to realize the anticipated opportunities from our acquisition of the global branded pharmaceuticals business from The Procter and Gamble Company; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2009 and from time-to-time in our other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be
'/>"/>

SOURCE Warner Chilcott plc Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Warner Chilcott to Present at UBS Global Life Sciences Conference
2. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
3. Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance
4. Warner Chilcott Announces Earnings Release Date and Conference Call for Second Quarter 2010 Financial Results
5. Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product
6. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
7. Warner Chilcott to Present at the Wells Fargo Securities Healthcare Conference
8. Warner Chilcott to Present at the Bank of America Merrill Lynch Healthcare Conference
9. Warner Chilcott Announces Earnings Release Date and Conference Call For First Quarter 2010 Financial Results
10. Warner Chilcott Announces 2010 Financial Guidance Conference Call
11. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015